International Edition
Latest News
Health

Etripamil Nasal Spray Converts Two-Thirds of Recurrent PSVT After Ablation in RAPID Subgroup

Cardamyst nasal spray converted approximately two-thirds of patients with recurrent paroxysmal supraventricular tachycardia following prior catheter ablation back to a normal heart rhythm within 30 minutes, according to new data announced by Milestone Pharmaceuticals on November 2, 2026.…

Etripamil Nasal Spray Converts Two-Thirds of Recurrent PSVT After Ablation in RAPID Subgroup

Cardamyst nasal spray converted approximately two-thirds of patients with recurrent paroxysmal supraventricular tachycardia following prior catheter ablation back to a normal heart rhythm within 30 minutes, according to new data announced by Milestone Pharmaceuticals on November 2, 2026.

The findings come from a subgroup analysis of the Phase 3 RAPID clinical trial, which evaluated the investigational drug in patients experiencing acute episodes of atrioventricular-nodal-dependent supraventricular tachycardia. The study results were prepared for presentation at the American Heart Association Scientific Sessions 2026 in Chicago, according to cardiacrhythmnews.com.

Catheter ablation successfully treats rapid heart rhythms for most patients, but a small subset continues to experience episodes afterward, as reported by GlobeNewswire. Prior ablation was reported in 6.6% of all randomized patients in the trial, representing 46 out of 692 participants, and in 6% of those with confirmed PSVT in the efficacy population.

Within the prior-ablation subgroup involving 11 patients, 66.7% of six patients treated with etripamil converted to sinus rhythm at 30 minutes. By comparison, 20% of five patients who received a placebo achieved conversion, according to cardiacrhythmnews.com. Patients in this specific subgroup had a mean age of 50.9 years, and 82% were female, with 54.5% taking oral AV nodal-acting medications.

“Most patients do well after ablation but a subset continues to have episodes, and we have had limited options to offer them for treating an episode outside of an emergency room setting,” said James E. Ip, Professor of Medicine and Director of Cardiac Pacing and Implantable Devices at Weill Cornell Medicine, told Cardiac Rhythm News.

Ip added that having a self-administered option should be part of discussions for patients considering a repeat procedure.

The broader RAPID trial evaluated a symptom-prompted, repeat-dose regimen of 70 mg etripamil nasal spray administered during perceived episodes. Before randomization, participants received a test dose of etripamil followed by another dose 10 minutes later to evaluate tolerability and train them on study procedures, as detailed by HCPLive.

In the overall study population of 692 randomly assigned patients, 184 self-administered the drug for confirmed PSVT. Kaplan-Meier estimates from that broader efficacy group showed 30-minute conversion rates of 64% with etripamil versus 31% with placebo, according to HCPLive. Treatment-emergent adverse events occurred in 50% of the broader etripamil group and 11% of the placebo group.

For the prior-ablation subgroup, researchers assessed safety using continuous electrocardiogram recordings and adverse-event reporting. Monitoring specifically watched for atrioventricular block and prolonged pauses, with no distinct safety signals emerging in these patients.

Weill Cornell Medicine, the medical school of Cornell University founded on April 14, 1898, with an endowment by Col. Oliver H. Payne, became affiliated with New York Hospital in 1913. The institutions opened a joint campus in Yorkville in 1932. In 1998, the college was renamed after Sanford I. Weill pledged a $100 million donation for biomedical research. The school was rebranded as Weill Cornell Medicine in 2015.

“In this analysis from the RAPID trial, patients with recurrent PSVT after a prior ablation responded to etripamil in a manner consistent with the overall trial population,” said David Bharucha, Chief Medical Officer of Milestone Pharmaceuticals, according to GlobeNewswire.

About the author: Health Desk

Health Desk at Archynewsy.